Affimed’s Phase I AFM13 had its Likelihood of Approval (LoA) in B-cell non-Hodgkin lymphoma slashed in half on the back of preclinical data released on 13 May. The data showed that Hodgkin lymphoma patient-derived natural killer (NK) cells, when combined with AFM13, did not reach the same level of cytotoxicity compared with healthy donor-derived NK cells.
AFM13 previously had an LoA of 28%, dropping to 14% as of 17 May. The 14-point drop was determined analysed from a combination of machine learning and proprietary algorithm.
The investigator-led Phase I AFM13 trial is recruiting 30 recurrent or refractory CD30-positive Hodgkin or non-Hodgkin lymphoma patients. AFM13 works by inducing the innate immune system to eliminate CD30-positive hematologic tumour cells. It is the company’s most advanced asset featuring its innate cell engager mechanism.
Affimed has a $1.11bn market cap.
Reynald Castaneda is an Associate Editor for Clinical Trials Arena parent company GlobalData’s investigative journalism team. A version of this article originally appeared on the Insights module of GlobalData’s Pharmaceutical Intelligence Center. To access more articles like this, visit GlobalData.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData